Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $192 | $165 | $150 | $174 |
| % Growth | 16.1% | 10.4% | -14% | – |
| Cost of Goods Sold | $48 | $17 | $16 | $26 |
| Gross Profit | $144 | $149 | $134 | $148 |
| % Margin | 74.8% | 89.8% | 89.5% | 85% |
| R&D Expenses | $29 | $22 | $27 | $29 |
| G&A Expenses | $0 | $28 | $27 | $25 |
| SG&A Expenses | $180 | $94 | $90 | $79 |
| Sales & Mktg Exp. | $0 | $65 | $63 | $55 |
| Other Operating Expenses | -$5 | $21 | $27 | $19 |
| Operating Expenses | $204 | $136 | $144 | $127 |
| Operating Income | -$60 | $12 | -$10 | $21 |
| % Margin | -31.4% | 7.3% | -6.8% | 12.3% |
| Other Income/Exp. Net | $2 | $5 | $4 | $5 |
| Pre-Tax Income | -$58 | $17 | -$6 | $26 |
| Tax Expense | -$13 | -$6 | $6 | $11 |
| Net Income | -$45 | $22 | -$12 | $15 |
| % Margin | -23.5% | 13.6% | -7.9% | 8.8% |
| EPS | -0.8 | 0.4 | -0.21 | 0.28 |
| % Growth | -300% | 290.5% | -175% | – |
| EPS Diluted | -0.8 | 0.4 | -0.21 | 0.27 |
| Weighted Avg Shares Out | 56 | 56 | 56 | 55 |
| Weighted Avg Shares Out Dil | 57 | 57 | 56 | 56 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $5 | $4 | $5 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $21 | $21 | $20 | $19 |
| EBITDA | -$37 | $33 | $18 | $45 |
| % Margin | -19.1% | 20.2% | 11.9% | 26% |